46 results about "Drug levels" patented technology

Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.

The present invention includes systems and methods for monitoring therapeutic drug concentration in blood by detecting markers, such as odors, upon exhalation by a patient after the drug is taken, wherein such markers result either directly from the drug itself or from an additive combined with the drug. In the case of olfactory markers, the invention preferably utilizes electronic sensor technology, such as the commercial devices referred to as “artificial” or “electronic” noses or tongues, to non-invasively monitor drug levels in blood. The invention further includes a reporting system capable of tracking drug concentrations in blood (remote or proximate locations) and providing the necessary alerts with regarding to ineffective or toxic drug dosages in a patient.

The invention relates to a fluorine-containing optically active composition for anti-infection, in particular to a quinolones optically active fluorine-containing composition anti-infective drug, i.e. a quinolones optically active fluorine-containing composition 1 showed by a right formula, wherein HA in the right formula is organic acid or inorganic acid which can form a composition accepted by pharmacology with (S)-6-fluorine-1-methyl-4-oxo-7-(1-piperazinyl)-1H and 4H-(1, 3) sulfur azetidine combined with (3, 2-a) quinoline-3-carboxylic acid. The quinolones optically active fluorine-containing composition 1 has stable property; compared with ulifloxacin, the quinolones optically active fluorine-containing composition 1 improves the water solubility and lowers the pH value of a water solution, is easy to dissolve in water and has higher biological activity, little renal toxicity and no skin and muscle irritation; the drug level of unobserved untoward effect is 30 mg / kg and is enhanced by 10 times comparing with the ulifloxacin, thus the quinolones optically active fluorine-containing composition 1 has low side effect and wide antimicrobial spectrum, and the activity of the quinolones optically active fluorine-containing composition 1 is 1-3 times higher than that of the racemic ulifloxacin.

A complex formulation for oral administration comprising a sustained release formulation of an HMG-CoA reductase inhibitor and a film layer for rapid release of an anti-hypertensive agent, the film layer being coated on the sustained release formulation, can achieve improved therapeutic effects of the anti-hypertensive agent by promptly releasing it, while maintaining a constant drug level of the HMG-CoA reductase inhibitor in blood through a slow release. Accordingly, the complex formulation is useful for preventing and treating diseases such as hyperlipidemia, atherosclerosis, hypertension and cardiovascular disease.

The present invention describes methods and devices for reducing the workload of instilling medication and allowing the clinician-user to control the associated procedure. The drug delivery device 122 is controlled to achieve a target drug concentration or a predetermined infusion rate waveform at a selected site of the patient. The time profile of the target drug concentration or predetermined infusion rate waveform is controlled by a drug state model (38) using clinical heuristics to achieve safe, predetermined changes in target drug concentration or infusion rate and target drug concentration or infusion rate. User-controlled change of note speed. The present invention allows time to assess a patient's response to changes in drug levels by making small increments and steady changes in drug levels over time.

The invention discloses a percutaneous give drug system, which comprises: a drug storeroom, the gel drug layer comprises drug, solvent, transdermal accelerating agent and gelatinizing agent; one adsorption layer comprised solvent absorption material of solvent in absorbable drug storeroom; one isolating layer between drug storeroom and adsorption layer, which is of non-woven fabrics or semipermeable membrane to make solvent of gas or liquid pass through successfully; adsorption layer can joint isolating layer of drug storeroom in opposite directions of closing up to skin of drug storeroom. The percutaneous give drug system in this invention can increase drug level in drug storeroom of the system to elevate drug transdermal speed, as well as increase controlled release effect of percutaneous give drug and absolute bioavailability, enhance drug curative effect, decrease drug waste, and depress preparation cost of the system. The invention is fit particular to percutaneous give drug system for water-soluble drug of propranolol hydrochloride, verapamil hydrochloride and chlorpromazine hydrochloride.

The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient a composition that includes a phenothiazine and another active agent, where predetermined plasma drug levels are achieved and maintained for 12 hours or more.

The invention provides a preparation method of oleanolic acid slow-release nano-microcapsules. The aim was to design and optimize oleanolic acid (OA) nanoparticles of poorly water-soluble drugs to improve their oral bioavailability and prolong the duration of therapeutic drug levels. The nanoparticle wall material is an amphiphilic polymer formed by hydrophilic chitosan oligosaccharide and hydrophobic deoxycholic acid. The particle size of nanoparticles of different wall materials is between 200-400nm, and the distribution is relatively uniform. In vitro release experiments were carried out in a simulated gastrointestinal tract environment, and the results showed that oleanolic acid nanocapsules released slowly in simulated gastric juice, and gradually released in intestinal juice; in the initial stage of release in PBS solution, it showed a burst release, and then released slowly; The sustained-release effect of oleanolic acid nano-microcapsules in each solution is remarkable. The oleanolic acid slow-release nano-microcapsules of the invention improve the bioavailability of the oleanolic acid, have obvious sustained-release effect in vitro, and can be used as an effective oral preparation for future liver injury treatment.